Matthew E Burow Selected Research

MicroRNAs (MicroRNA)

1/2021	Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling.
1/2017	MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance.
9/2016	Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation.
6/2015	Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
1/2014	Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells.
4/2013	Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition.
2/2013	Phytoalexins, miRNAs and breast cancer: a review of phytochemical-mediated miRNA regulation in breast cancer.
7/2012	The microRNA expression associated with morphogenesis of breast cancer cells in three-dimensional organotypic culture.
1/2012	Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.
1/2012	Endocrine disruptor regulation of microRNA expression in breast carcinoma cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew E Burow Research Topics

Disease

83	Neoplasms (Cancer) 10/2023 - 05/2004
79	Breast Neoplasms (Breast Cancer) 03/2023 - 08/2002
20	Carcinogenesis 02/2024 - 06/2008
20	Neoplasm Metastasis (Metastasis) 02/2024 - 01/2008
20	Triple Negative Breast Neoplasms 03/2023 - 05/2012
9	Obesity 02/2024 - 01/2013
6	Carcinoma (Carcinomatosis) 10/2023 - 07/2011
4	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 12/2002
3	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 05/2011
3	Osteoporosis 04/2017 - 08/2014
3	Ovarian Neoplasms (Ovarian Cancer) 01/2010 - 12/2006
3	Adenocarcinoma 05/2006 - 07/2002
2	Disease Progression 01/2021 - 09/2016
2	Uterine Neoplasms (Uterine Cancer) 01/2019 - 02/2014
2	Inflammation (Inflammations) 02/2015 - 04/2009
2	Glioblastoma (Glioblastoma Multiforme) 10/2011 - 07/2011
2	Hypoxia (Hypoxemia) 01/2009 - 12/2002

Drug/Important Bio-Agent (IBA)

30	Estrogens (Estrogen)FDA Link 03/2023 - 12/2002
25	Estrogen ReceptorsIBA 03/2022 - 09/2006
18	Hormones (Hormone)IBA 03/2023 - 06/2008
13	MicroRNAs (MicroRNA)IBA 01/2021 - 11/2011
12	Proteins (Proteins, Gene)FDA Link 03/2023 - 08/2002
12	Phosphotransferases (Kinase)IBA 01/2023 - 07/2011
12	Estrogen Receptor alphaIBA 10/2022 - 05/2005
11	Tamoxifen FDA LinkGeneric 06/2021 - 09/2006
9	p38 Mitogen-Activated Protein KinasesIBA 01/2019 - 12/2002
8	Mitogen-Activated Protein KinasesIBA 03/2023 - 10/2012
7	glyceollinIBA 03/2023 - 01/2006
7	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 12/2006
5	Messenger RNA (mRNA)IBA 03/2023 - 12/2002
5	Phenobarbital (Luminal)FDA Link 08/2021 - 07/2012
5	LeptinIBA 03/2019 - 01/2013
5	SphingolipidsIBA 02/2014 - 11/2009
5	PhytoalexinsIBA 02/2013 - 01/2006
5	sphingosine kinaseIBA 07/2012 - 11/2010
4	Aromatase InhibitorsIBA 03/2023 - 01/2013
4	Letrozole (Femara)FDA LinkGeneric 03/2023 - 01/2013
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2006
4	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2013
4	CytokinesIBA 01/2023 - 06/2004
4	Fulvestrant (Faslodex)FDA Link 05/2021 - 01/2010
4	LigandsIBA 05/2021 - 01/2010
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 03/2005
4	PanobinostatIBA 01/2020 - 05/2012
4	Protein Isoforms (Isoforms)IBA 09/2016 - 12/2010
4	DDTIBA 01/2015 - 01/2009
4	3- (4- chlorophenyl)- adamantane- 1- carboxylic acid (pyridin-4-ylmethyl)amideIBA 02/2014 - 11/2010
4	CeramidesIBA 06/2012 - 05/2004
3	Collagen Type I (Type I Collagen)IBA 10/2023 - 07/2011
3	PhytochemicalsIBA 03/2023 - 09/2009
3	EnzymesIBA 01/2023 - 06/2011
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 09/2006
3	CollagenIBA 01/2022 - 01/2021
3	matrigelIBA 01/2021 - 01/2010
3	Histone Deacetylase InhibitorsIBA 01/2020 - 01/2012
3	MelatoninIBA 01/2019 - 05/2005
3	Small Interfering RNA (siRNA)IBA 01/2019 - 06/2008
3	ClaudinsIBA 06/2018 - 08/2016
3	SphingosineIBA 02/2014 - 05/2004
3	ProteomeIBA 03/2012 - 01/2008
2	Histones (Histone)IBA 02/2024 - 11/2017
2	ChromatinIBA 02/2024 - 11/2017
2	HydrogelsIBA 10/2023 - 11/2017
2	NIMA-Related KinasesIBA 03/2023 - 01/2021
2	human ERBB2 proteinIBA 03/2023 - 12/2010
2	Lapatinib (GW572016)FDA Link 03/2023 - 03/2022
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2023 - 01/2022
2	Everolimus FDA Link 01/2023 - 10/2014
2	Transcription Factors (Transcription Factor)IBA 04/2022 - 08/2021
2	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 05/2011
2	AndrogensIBA 01/2022 - 02/2014
2	AdipokinesIBA 01/2022 - 02/2015
2	MitogensIBA 01/2022 - 01/2012
2	romidepsin (FK228)FDA Link 01/2022 - 01/2020
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2022
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2021 - 01/2021
2	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 08/2015
2	Metalloproteases (Metalloproteinases)IBA 01/2021 - 01/2019
2	PlasticsIBA 01/2021 - 07/2012
2	Cadherins (E-Cadherin)IBA 11/2017 - 12/2015
2	Cyclin D1IBA 11/2017 - 11/2009
2	Estradiol (Delestrogen)FDA LinkGeneric 01/2017 - 09/2012
2	Endocrine DisruptorsIBA 01/2016 - 01/2012
2	ChemokinesIBA 02/2015 - 01/2011
2	daidzeinIBA 08/2014 - 08/2010
2	Death Domain ReceptorsIBA 04/2013 - 01/2012
2	Progesterone FDA LinkGeneric 02/2013 - 05/2012
2	flavoneIBA 10/2012 - 07/2002
2	Chalcone (Benzalacetophenone)IBA 10/2012 - 07/2002
2	Insulin (Novolin)FDA Link 06/2012 - 01/2012
2	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 06/2012 - 06/2011
2	afimoxifene (hydroxytamoxifen)IBA 03/2012 - 01/2010
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2012 - 12/2002
2	Sorafenib (BAY 43-9006)FDA Link 10/2011 - 07/2011
2	Pemetrexed (MTA)FDA Link 10/2011 - 07/2011
2	Estrogen Receptor betaIBA 09/2006 - 05/2006

Therapy/Procedure

38	Therapeutics 03/2023 - 08/2004
4	Drug Therapy (Chemotherapy) 01/2012 - 01/2008
3	Lasers (Laser) 11/2017 - 09/2015
2	Immunotherapy 10/2023 - 01/2019